H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions - antibiotic resistance).
H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013 (Medicare-related provisions).
H. J. Res. 117, Continuing Appropriations Resolution, 2013 (Medicare-related provisions).
Medical research.
Antibiotic resistance issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
H.R. 5651, Food and Drug Administration Reform Act of 2012.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013.
H. J. Res. 117, Continuing Appropriations Resolution.
Medicare home infusion and reimbursement issues.
340B drug pricing program issues, including program expansion.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H.R. 5194, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
H.R. 5624, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
H.R. 6684, Spending Reduction Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Antibiotic resistance issues.
Pay-for-delay proposals and generic issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Prescription Drug User Fee Act reauthorization.H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012.
H.R. 6433, FDA User Fee Corrections Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Duration: December 1, 2007
to
December 31, 2012
General Issues: Budget/Appropriations , Health Issues , Medicare/Medicaid , Pharmacy , Copyright/Patent/Trademark , Defense
Spending: about $1,220,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate, U.S. Senate,, Centers For Medicare and Medicaid Services (CMS), Veterans Affairs - Dept of (VA), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Anne Marie Polak Leg Correspondent for Cong. Mike Ferguson
Leg. Correspondent for Rep. Mike Ferguson
John Scofield Comm Dir., House Approps. Committee
Comm. Dir., House Approps. Committee
Communications Dir., House Approps Committee
Lantie Slenzak Legislative Director, Rep. Gene Green
Leg. Dir. for Rep. Gene Green
Donni Turner Legislative Assistant, Senator Richard Durbin
Legislative Assistant, Sen. Richard Durbin
Oscar Ramirez Special Assistant to the Secretary of Labor
Chief of Staff to Rep. Hilda Solis
Deputy Chief of Staff for Rep. Al Green
Legislative Director for Rep. Joe Baca
Stephen Northrup Health Policy Director, Senate HELP Comtee
Health Policy Advisor, Sen. Michael Enzi
Tom Sparkman Health Policy Intern, Senate HELP Committee
Aranthan Jones II Policy Director, Rep James Clyburn
Chief of Staff/Policy Adv., Rep. Andre Carson
Health Policy Dir., Congressional Black Caucus
Israel Klein Dep. Dir. Communications, Joint Economics Ct
Communications Dir., Sen. Charles Schumer
Sr. Comm. Adv/Press Secy Rep. Edward Markey
Kay King Dir. Office of Inter-Parliamentary Affairs
Sr. Policy Adv. House Comtee on For. Affairs
Sr. Policy Adv., Rep. Tom Lantos
Chief of Staff, Rep. Richard Swett
Staff, Employmt and Housing Subcommittee
Sharon Cohen n/a
Thomas Sparkman n/a
Daniele Baierlein n/a
Andrew Kauders n/a
Nicole Collier n/a
Steve Northrup n/a
Christina Antelo n/a
Thomas Borck n/a
Jennifer Bowman n/a
Cristina Antelo n/a
Nicole Young n/a
Randall Gerard n/a
Timothy Glassco n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2012
PODESTA GROUP, INC. terminated an engagement in which they represented Cubist Pharmaceuticals, Inc. on Jan. 22, 2013.
Original Filing: 300542756.xml
Lobbying Issues
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions - antibiotic resistance).
H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013 (Medicare-related provisions).
H. J. Res. 117, Continuing Appropriations Resolution, 2013 (Medicare-related provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical research.
Antibiotic resistance issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
H.R. 5651, Food and Drug Administration Reform Act of 2012.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013.
H. J. Res. 117, Continuing Appropriations Resolution.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare home infusion and reimbursement issues.
340B drug pricing program issues, including program expansion.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H.R. 5194, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
H.R. 5624, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
H.R. 6684, Spending Reduction Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Antibiotic resistance issues.
Pay-for-delay proposals and generic issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Prescription Drug User Fee Act reauthorization.H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012.
H.R. 6433, FDA User Fee Corrections Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on Oct. 22, 2012.
Original Filing: 300518681.xml
Lobbying Issues
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).
H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
H. J. Res. 117, Continuing Appropriations Resolution, 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical research.
Antibiotic resistance issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
H.R. 5651, Food and Drug Administration Reform Act of 2012.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013.
H. J. Res. 117, Continuing Appropriations Resolution.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare home infusion and reimbursement issues.
340B drug pricing program issues, including program expansion.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H.R. 5194, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
H.R. 5624, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Antibiotic resistance issues.
Pay-for-delay proposals and generic issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Prescription Drug User Fee Act reauthorization.H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012.
H.R. 6433, FDA User Fee Corrections Act of 2012.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on July 20, 2012.
Original Filing: 300496494.xml
Lobbying Issues
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).
H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical research.
Antibiotic resistance issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
H.R. 5651, Food and Drug Administration Reform Act of 2012.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013.
2013 Labor-HHS Appropriations (House) (no bill).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare home infusion and reimbursement issues.
340B issues.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H.R. 5194, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
H.R. 5624, Rural Hospital and Provider Equity and 340B Improvement Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Antibiotic resistance issues.
Pay-for-delay proposals and generic issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Prescription Drug User Fee Act reauthorization.H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act
S. 2289, Better Pharmaceuticals and Devices for Children Act of 2012.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on April 20, 2012.
Original Filing: 300471464.xml
Lobbying Issues
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical research.
Antibiotic resistance issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare home infusion and reimbursement issues.
340B issues.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions).Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Antibiotic resistance issues.
Pay-for-delay proposals and generic issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Prescription Drug User Fee Act reauthorization.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on Jan. 20, 2012.
Original Filing: 300452455.xml
Lobbying Issues
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.
H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.
H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.
H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.H.R. 3070 / S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical research.
Antibiotic resistance issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare home infusion and reimbursement issues.
340B issues.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.
H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.
H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.
H.R. 3070 / S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Antibiotic resistance issues.
Pay-for-delay proposals and generic issues.
H.R. 2182 / S. 1734, Generating Antibiotic Incentives Now Act of 2011.
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.
H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.
H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.
H.R. 3070 / S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on Oct. 20, 2011.
Original Filing: 300426075.xml
Lobbying Issues
FY 2012 budget resolutions.
FY 2011/2012 appropriations for antibiotic resistance research.
Monitor debt ceiling negotiations.
H.R. 2017, Continuing Appropriations Act, 2012.H.R. 2608, Continuing Appropriations Act, 2012.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
S. 1599, Labor-HHS Appropriations.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical research.
Antibiotic resistance issues.
H.R. 2182, Generating Antibiotic Incentives Now Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare home infusion and reimbursement issues.
340B issues.
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011.
Medicare reimbursement issues.H.R. 2017, Continuing Appropriations Act, 2012.
H.R. 2608, Continuing Appropriations Act, 2012.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Antibiotic resistance issues.
H.R. 2182, Generating Antibiotic Incentives Now Act of 2011.
Pay-for-delay proposals and generic issues.
H.R. 2017, Continuing Appropriations Act, 2012.H.R. 2608, Continuing Appropriations Act, 2012.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2011
In Q2, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on July 20, 2011.
Original Filing: 300401962.xml
Lobbying Issues
FY 2012 budget resolutions.
FY 2011/2012 appropriations for antibiotic resistance research.
Monitor debt ceiling negotiations, generally.
H.R. 1473, Department of Defense and Full-Year Continuing Appropriations Act of 2011
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical research.
Antibiotic resistance issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare home infusion and reimbursement issues.
340B issues
H.R. 2195 / S. 1203, Medicare Home Infusion Therapy Coverage Act of 2011
Agencies Lobbied
U.S. Senate
Lobbying Issues
Antibiotic resistance issues.
H.R. 2182, Generating Antibiotic Incentives Now Act of 2011
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on April 20, 2011.
Original Filing: 300374615.xml
Lobbying Issues
H.R. 1, Full Year Continuing Appropriations Act, 2011
H.J. Res. 44 and 48, Further Continuing Appropriations Amendments, 2011
FY 2012 Budget resolutions.
FY 2011/2012 appropriations for antibiotic resistance research.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical research.
Antibiotic resistance issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare home infusion and reimbursement issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Antibiotic resistance issues.
GAIN: Generating Antibiotic Incentives Now Act of 2011
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $90,000. The report was filed on Jan. 20, 2011.
Original Filing: 300353397.xml
Lobbying Issues
P.L. 111-148 Patient Protection and Affordable Care Act implementation
P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provision)
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322
H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317
H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
P.L. 111-148 Patient Protection and Affordable Care Act implementation
P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementationH.R. 6331 Generating Antibiotic Incentives Now Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 (340B provisions)
H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286 (340B provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Coverage Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) P.L. 111-148 Patient Protection and Affordable Care Act implementation
P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provisions)
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322
H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317
H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 (340B provisions)
H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286 (340B provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Antibiotic resistance and wounded troops
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
PODESTA GROUP, INC. amended a lobbying report for representation of Cubist Pharmaceuticals, Inc. in Q32010 on Nov. 2, 2012.
Original Filing: 300523011.xml
Lobbying Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provision)
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Coverage Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
S. Amdt. (Baucus) to H.R. 4849 Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions)
H.R. 1586 Education Jobs and Medicaid Funding Bill (AMP Revisions)
H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions and "Pay to Delay" Provision)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provisions)
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Antibiotic resistance and wounded troops
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $90,000. The report was filed on Oct. 20, 2010.
Original Filing: 300328773.xml
Lobbying Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provision)
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Coverage Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
S. Amdt. (Baucus) to H.R. 4849 Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions)
H.R. 1586 Education Jobs and Medicaid Funding Bill (AMP Revisions)
H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions and "Pay to Delay" Provision)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provisions)
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Antibiotic resistance and wounded troops
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on July 19, 2010.
Original Filing: 300293308.xml
Lobbying Issues
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010H.R. 4213 American Jobs and Closing Tax Loopholes Act of 2010
H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Coverage Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R. 3590 Patient Protection and Affordable Care ActH.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 American Jobs and Closing Tax Loopholes Act of 2010
H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
H.R. 3962 Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2010
In Q1, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $60,000. The report was filed on April 20, 2010.
Original Filing: 300273012.xml
Lobbying Issues
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010H.R. 4213 Workers, State, and Business Relief Act of 2010
H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Coverage Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R. 3590 Patient Protection and Affordable Care ActH.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 Workers, State, and Business Relief Act of 2010
H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2009
In Q4, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $70,000. The report was filed on Jan. 19, 2010.
Original Filing: 300238544.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
H.R. 1 American Recovery and Reinvestment Act of 2009S. Con. Res. 13
H. Con. Res. 85
H.R. 3288 Consolidated Appropriations Act, 2010, LHHS - Division D
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
S. 1679 Affordable Health Choices Act
H.R. 3200 American Affordable Health Choices Act of 2009Tri Caucus Healthcare Reform Bill
S. 1796 Americas Healthy Future Act of 2009
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)
H.R. 2937 MRSA Infection Prevention and Patient Protection Act
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
H.R. 3962 Affordable Health Care for America Act
H.R. 3590 Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Coverage Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
S. 301 Physician Payments Sunshine Act of 2009S. 1679 Affordable Health Choices Act
H.R. 3200 American Affordable Health Choices Act of 2009
Tri Caucus Healthcare Reform Bill
S. 1796 Americas Healthy Future Act of 2009
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
H.R. 3962 Affordable Health Care for America Act
H.R. 3590 Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2009
In Q3, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $70,000. The report was filed on Oct. 17, 2009.
Original Filing: 300208710.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
H.R. 1 American Recovery and Reinvestment Act of 2009S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
Kennedy American Affordable Health Choices Act of 2009
H.R. 3200 American Affordable Health Choices Act of 2009Tri Caucus Healthcare Reform Bill
Baucus/Finance Healthcare Reform Bill - America's Healthy Future Act of 2009
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)
H.R. 2937 MRSA Infection Prevention and Patient Protection Act
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
S. 301 Physician Payments Sunshine Act of 2009Kennedy American Affordable Health Choices Act of 2009
H.R. 3200 American Affordable Health Choices Act of 2009
Tri Caucus Healthcare Reform Bill
Baucus/Finance Healthcare Reform Bill - America's Healthy Future Act of 2009
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2009
In Q2, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $70,000. The report was filed on July 20, 2009.
Original Filing: 300191888.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
H.R. 1 American Recovery and Reinvestment Act of 2009S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
Kennedy Healthcare Reform Bill
House Tri Committee Healthcare Reform BillTri Caucus Healthcare Reform Bill
Senate Finance Healthcare Reform Bill
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)
H.R. 2937 MRSA Infection Prevention and Patient Protection Act
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
S. 301 Physician Payments Sunshine Act of 2009Kennedy Healthcare Reform Bill
House Tri Committee Healthcare Reform Bill
Tri Caucus Healthcare Reform Bill
Senate Finance Healthcare Reform Bill
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2501 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)H.R. 2937 MRSA Infection Prevention and Patient Protection Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2009
In Q1, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $70,000. The report was filed on April 19, 2009.
Original Filing: 300155849.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
H.R. 1 American Recovery and Reinvestment Act of 2009S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription drug/Federal Drug Admin/Center for Disease Control/Health and Human Service issues
Antibiotic Resistance issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2008
In Q4, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $40,000. The report was filed on Jan. 21, 2009.
Original Filing: 300128595.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
House Concurrent Resolution 312 FY09 Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance ActH. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
H.R. 1424, Emergency Economic Stabilization Act of 2008
H Res. 988, Designating the month of March 2008 as `MRSA Awareness Month'
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
S. 3560 QI Program Supplemental Funding Act of 2008 (Antibiotic Provision)
S Res. 454, Designating the month of March 2008 as `MRSA Awareness Month'
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage issues
H. R. 2567, Medicare Home Infusion Therapy Coverage Act of 2007
S. 870, Medicare Home Infusion Therapy Consolidated Coverage Act of 2007
S. 3505, Medicare Home Infusion Therapy Coverage Act of 2008S. 2029, Physician Payments Sunshine Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription drug/Federal Drug Admin/Center for Disease Control/Health and Human Service issues
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance Act
H. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
S. 3560 QI Program Supplemental Funding Act of 2008 (Antibiotic Provision)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1908, Patent Reform Act of 2007
S. 1145, Patent Reform Act of 2007
S. 3600, Patent Reform Act of 2008
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2008
In Q3, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $40,000. The report was filed on Oct. 20, 2008.
Original Filing: 300102569.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009House Concurrent Resolution 312 FY09 Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance ActH. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
H.R. 1424, Emergency Economic Stabilization Act of 2008
H Res. 988, Designating the month of March 2008 as `MRSA Awareness Month'
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
S. 3560 QI Program Supplemental Funding Act of 2008 (Antibiotic Provision)
S Res. 454, Designating the month of March 2008 as `MRSA Awareness Month'
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage issues
H. R. 2567, Medicare Home Infusion Therapy Coverage Act of 2007
S. 870, Medicare Home Infusion Therapy Consolidated Coverage Act of 2007
S. 3505, Medicare Home Infusion Therapy Coverage Act of 2008H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription drug/Federal Drug Admin/Center for Disease Control/Health and Human Service issues
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance Act
H. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
S. 3560 QI Program Supplemental Funding Act of 2008 (Antibiotic Provision)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1908, Patent Reform Act of 2007
S. 1145, Patent Reform Act of 2007
S. 3600, Patent Reform Act of 2008
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2008
In Q2, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $40,000. The report was filed on July 21, 2008.
Original Filing: 300082829.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
House Concurrent Resolution 312 FY09 Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance ActH. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
S Res. 454, Designating the month of March 2008 as `MRSA Awareness Month'
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage issues
H. R. 2567, Medicare Home Infusion Therapy Coverage Act of 2007
S. 870, Medicare Home Infusion Therapy Consolidated Coverage Act of 2007
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription drug/Federal Drug Admin/Center for Disease Control/Health and Human Service issues
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance Act
H. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1908, Patent Reform Act of 2007
S. 1145, Patent Reform Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2008
In Q1, PODESTA GROUP, INC. lobbied for Cubist Pharmaceuticals, Inc. , earning $40,000. The report was filed on April 16, 2008.
Original Filing: 300039692.xml
Lobbying Issues
Medical Research
Antibiotic Resistance issues
LHHS Appropriations
House Concurrent Resolution 312 FY09 Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance ActH. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage issues
H. R. 2567, Medicare Home Infusion Therapy Coverage Act of 2007
S. 870, Medicare Home Infusion Therapy Consolidated Coverage Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medical Research
Prescription drug/Federal Drug Admin/Center for Disease Control/Health and Human Service issues
Antibiotic Resistance issues
H. R. 1174, Healthy Hospitals Act
H. R. 3697, Strategies to Address Antimicrobial Resistance Act
H. R. 4352, Antimicrobial Task Force in public schools
H. R. 4451, MRSA Research and Study Act
S. 2278, Community and Healthcare Associated Infections Reduction Act
S. 2313, Strategies to Address Antimicrobial Resistance Act
S. 2525, MRSA Infection Prevention and Patient Protection Act
S. 2526, Worker Infection Protection Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1908, Patent Reform Act of 2007
S. 1145, Patent Reform Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2007
PODESTA GROUP, INC. filed a lobbying registration on Jan. 3, 2008 to represent Cubist Pharmaceuticals, Inc., effective Dec. 1, 2007.
Original Filing: 300002607.xml
Issue(s) they said they’d lobby about: Medicare coverage issues
Medical Research
Prescription drug/Food and Drug Administration/Center for Disease Control/Health and Human Service issues
Antibiotic Resistance issues .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...